BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao L, Feng Z, Li Q, Li L, Chen L, Xiao T. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma. Tumour Biol. 2014;35:2997-3002. [PMID: 24248544 DOI: 10.1007/s13277-013-1386-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Jeong SY, Jang HJ, Park ST, Kim HS. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:762528. [PMID: 34737965 DOI: 10.3389/fonc.2021.762528] [Reference Citation Analysis]
2 Chou CH, Hsieh MJ, Chuang CY, Lin JT, Yeh CM, Tseng PY, Yang SF, Chen MK, Lin CW. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. Oncotarget 2017;8:96225-38. [PMID: 29221201 DOI: 10.18632/oncotarget.21958] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
3 Moazeni-Roodi A, Sarabandi S, Karami S, Hashemi M, Ghavami S. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer. Biosci Rep 2020;40:BSR20192051. [PMID: 33017009 DOI: 10.1042/BSR20192051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Peng T, Sun Y, Lv Z, Zhang Z, Su Q, Wu H, Zhang W, Yuan W, Zuo L, Shi L, Zhang LF, Zhou X, Mi Y. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. Sci Rep 2021;11:1373. [PMID: 33446698 DOI: 10.1038/s41598-020-80146-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xiong SW, Ma J, Feng F, Fu W, Shu SR, Ma T, Wu C, Liu GC, Zhu J. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget 2017;8:25300-9. [PMID: 28445975 DOI: 10.18632/oncotarget.15811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Li J, Mai J. Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma. Tumour Biol 2014;35:11295-300. [PMID: 25117075 DOI: 10.1007/s13277-014-2440-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148 [PMID: 30949443 DOI: 10.5306/wjco.v10.i3.136] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Cencini E, Sicuranza A, Fabbri A, Ferrigno I, Rigacci L, Cox MC, Raspadori D, Bocchia M. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. Br J Haematol 2019;184:223-31. [PMID: 30203425 DOI: 10.1111/bjh.15582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]